L01FX20 · Antineoplastic and immunomodulating agents
Tremelimumab AstraZeneca
Indications
Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
Composition
- Active substance
- tremelimumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tremelimumab AstraZeneca
- Active substance
- tremelimumab
- ATC code
- L01FX20
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- Marketing authorisation holder
- AstraZeneca AB